Did you know that the global neuromodulation market is projected to reach $6B by the end of 2024? Or that we project the market will grow at a CAGR of 5.0% from 2023 to 2028? These are the types of questions you can answer with our Neuromodulation Market Intelligence Package. This focused package provides you with actionable insights for market sizing, due diligence, trend analysis, competitive analysis, commercial planning, and much more. Here's what's included in our indication-specific packages: • Global Procedure Volumes: Data for 37 countries spanning 2018–2030. • Market Trends: Historical and forecasted estimates for the global medical device market. • Comprehensive Reports: Access all published research for your chosen package. • Innovator Insights: Stay informed on startups and growth-stage companies reshaping your market. Whether you specialize in Neuromodulation, Cardiovascular, Orthopedics, or any of our other market-specific packages, our platform equips you with the data to make confident, forward-thinking decisions. Here are the other packages we offer: Neurosurgery, Neuromodulation/Neurostimulation, Urology, General Surgery, Orthopedics, Spine, Cardiology, Peripheral Vascular, Structural Heart, Neurovascular (Stroke), and Aesthetics. Secure 12 months of trusted data and insights with our Neuromodulation Market Intelligence Package—subscribe now or contact our team to learn how it can transform your strategy: https://lnkd.in/g8YSuANX

In October, Distalmotion (LSI USA ‘25 Innovator) was granted De Novo approval by the FDA to market the Dexter Surgical Robot for adult inguinal hernia repair. Distalmotion's mission is to empower hospitals, surgeons, and patients by removing the complexities of robotic surgery. Their goal is to establish a new standard of care, ensuring that patients in general, gynecologic, and urologic surgery have access to best-in-class minimally invasive care. The Dexter Surgical Robot embodies this vision, focusing on three key pillars: simplicity, accessibility, and excellence. The company also received CE mark approval for urology, general surgery, and gynecology at the end of 2020. Since then, they have successfully treated over 1,300 patients across France, Germany, Austria, and Switzerland. Distalmotion is dedicated to developing a robotic platform tailored to high-volume procedures, bringing the benefits of robotic-assisted surgery to outpatient settings. Congratulations to LSI Alumni Greg Roche and the Distalmotion team on this major milestone! To hear more, check out Greg Roche’s full presentation from LSI USA '24 on our website and YouTube channel, and meet him this March at LSI USA '25, where he’s set to present the latest updates.

What factors do investors consider when evaluating investment opportunities in AI technologies? At LSI Europe ‘24, our panel "AI Infrastructure and the Future of Imaging,” explored how AI is being used to enhance disease characterization, streamline clinical workflows, and personalize treatments. The discussion highlighted key investment opportunities in the space, along with the challenges AI companies face, such as healthcare system adoption, reimbursement hurdles, and infrastructure gaps. The panelists also shared their thoughts on the future of AI in healthcare, emphasizing the importance of finding scalable use cases and the role of precision medicine in driving AI innovation. The full panel, "AI Infrastructure and the Future of Imaging,” is available on our website and YouTube channel featuring: • Natasha Allen (Moderator) — Foley & Lardner LLP • Sahirzeeshan (Sahir) Ali — Modi Ventures • Imran Hamid, MD — LifeArc Ventures • Soyoung Park — 1004 Venture Partners • Vishal Gulati — Recode Ventures - Want to attend our next event? LSI USA ‘25 will be held March 17th-21st in Dana Point, California. Apply today on our website.

KēlaHealth (LSI Asia ‘25 Innovator) uses artificial intelligence and machine learning to transform surgical care. The company focuses on improving patient outcomes by integrating data-driven insights into surgical workflows. By analyzing large datasets from electronic health records, claims, and surgical case data, KelaHealth identifies patient-specific risks and provides actionable recommendations to support clinical decision-making. This approach enhances both safety and efficiency in surgery. The platform employs predictive analytics to anticipate risks such as complications, readmissions, and adverse events before surgery. Based on these insights, it suggests personalized interventions to help surgeons and care teams tailor care for each patient. With seamless integration into hospital workflows, KelaHealth delivers real-time insights at the point of care, making it adaptable to various surgical specialties and healthcare environments. Learn more about KelaHealth at LSI Asia ‘25 this June 10-13 where Bora Chang, MD has been selected to present. The event will take place at The Ritz-Carlton, Millenia Singapore. Want to join us at LSI Asia ‘25? Registration, applications for presenters, sponsorship opportunities, and our special hotel block rates are open. Secure your spot today on our website.

“As a startup founder, I travel a lot, and I've attended over the course of the last five, six years, probably a couple hundred conferences already, but LSI definitely stands out. LSI definitely stands out in the density of top people at the event. The production quality is super great, and eventually, I've reached a point where I need to start to narrow my travels to these events. I believe 100% LSI will stay on the list for the foreseeable future, for sure, and it's definitely one of my favorite conferences to attend.” - Martin Herman, CEO & Co-Founder of Powerful Medical - Want to join us in 2025? Our 2025 event schedule is now set with three events across the globe: • LSI USA '25: March 17th – 21st (Dana Point, CA) • LSI Asia '25: June 10th – 13th (Singapore) • LSI Europe '25: September 7th – 11th (London) Visit our website or connect with our team to secure your spot at the best rate for any of our 2025 events.

IAG Capital Partners (LSI USA ‘25 Investor) invests evergreen capital in early-stage companies ranging from late seed to Series B, focusing on three main categories: 1. Life Sciences, including medical devices, diagnostics and biotechnology platforms 2. Data-based SaaS companies across all industries — from AgTech to Robotics 3. Next-generation infrastructure, particularly companies at the intersection of high-performance and enterprise computing workflows. IAG is headquartered in Charleston, South Carolina, but intentionally global in outlook, seeking differentiation and innovation around the world. Their portfolio spans the US, the UK, and Europe. IAG Capital Partners Portfolio includes companies like: • Cognito Therapeutics, Inc. — Christian Howell • Elucid — Kelly Huang, PhD • Jana Care — Anh Hoang • VenoStent, Inc. — Timothy Boire • among others We’re excited to welcome Ehsan Jabbarzadeh, PhD, MBA, Venture Partner, and Anna Hildebrand, Analyst, at IAG Capital Partners to LSI USA ‘25 this March 17-21 in Dana Point, California. Want to see what other investors are joining us at LSI USA ‘25? Head over to our website to see a preview.

“Over the last 15 years, Medtech as an asset class has been deplorable.” - Duke Rohlen, Founder, CEO, and Chairman of Ajax Health In Duke Rohlen’s LSI Europe ‘24 Keynote, he outlines the challenges Medtech has faced as an investment class, citing high R&D costs, slow returns, and inefficiencies tied to single-product companies. Despite spending billions annually on innovation and acquisitions, major Medtech players struggle to develop transformative technologies internally. At the same time, venture-backed startups are often too risky and slow, making them unattractive to investors focused on shorter-term returns. Rather than polarizing innovation into low-risk incremental changes or high-risk transformational bets, Duke advocates for the middle path—targeting innovations that large firms often overlook and venture capitalists find insufficiently disruptive. Through the Growth Driver Model, Duke partners with external investors to create off-balance-sheet accelerators, developing innovations that leverage existing corporate capabilities while generating long-term growth. Catch Duke Rohlen’s full LSI Europe '24 keynote, “The Middle Path to Innovation”, on our website and YouTube channel. Featured panelists: • Mano Iyer (Moderator) — Sofinnova Partners • Duke Rohlen — Ajax Health - Want to attend our next event? LSI USA ‘25 will be held March 17th-21st in Dana Point, California. Apply today on our website.

Over the 2023 to 2028 forecast period, procedure volumes are expected to increase slowly at a 2.9% annual rate, up from 1.4% in the prior year’s analysis. Additionally, a re-analysis of sales in the sacral nerve modulation segment resulted in an increase of approximately $1 billion, equating to a 20% increase in the total market value. This makes the sacral nerve modulation product segment the fastest-growing product segment in the neuromodulation device market. Other neuromodulation devices, such as the Inspire hypoglossal nerve stimulator from Inspire Medical, have demonstrated significant market acceptance, with revenues increasing 142% from 2021 to 2023 to $565 million. Analyst Insights: Key Driving Factors Historically, neuromodulation devices have been used primarily for the treatment of chronic pain and movement disorders, such as Parkinson’s disease. However, there has been increased adoption of… Subscribe to The Lens Magazine by LSI to continue this article and get our upcoming December edition for free, along with all 12 monthly editions in 2025: https://lnkd.in/dZEXphUB

We are thrilled to introduce Gary Guthart, CEO and member of the Board of Directors at Intuitive, as our Keynote speaker for LSI USA '25. Dr. Guthart joined Intuitive as part of the first engineering team in 1996 as a control systems analyst. He was promoted to vice president of engineering in 1999, senior vice president of product operations in 2002, and four years later, he was appointed president and chief operating officer. Before joining Intuitive, Guthart was part of the core team developing foundational technology for computer-enhanced surgery at SRI International (formerly Stanford Research Institute), a renowned nonprofit scientific research organization. While at SRI, he also developed algorithms for vibration and acoustic control of large-scale systems. Guthart’s first scientific experience came early in his career in a human factors lab at NASA, where he supported a team studying human performance assessment of pilots. Dr. Guthart also serves on the Board of Directors for Illumina and holds a BS in engineering from the University of California Berkeley, along with an MS and PhD in engineering science from the California Institute of Technology. Want to get involved at LSI USA ‘25? We’re still accepting applications to present, exhibit, and attend the event. Apply on our website today for your opportunity to connect with the industry's top decision-makers at LSI USA ‘25 on March 17-21, 2025 in Dana Point California.

MIMOSA Diagnostics has achieved a transformative milestone in advancing the standard of care for diabetic foot ulcers and venous leg ulcers. In a groundbreaking decision, the Centers for Medicare and Medicaid Services (CMS) have updated their Local Coverage Determination (LCD) ruling to include vascular assessments, such as tissue oxygenation, as part of the standard requirements for skin substitutes and cellular tissue products. This policy change highlights the growing impact of innovative technologies like the MIMOSA Pro on improving patient outcomes. This milestone directly results from MIMOSA Diagnostics’ leadership and advocacy within the healthcare community. Earlier this year, the MIMOSA team rallied support from their network to submit letters to Medicare Administrative Contractors (MACs), emphasizing the importance of vascular assessments in wound care. Their efforts have culminated in this policy update, which formally integrates MIMOSA’s groundbreaking solution into the standard of care. At the heart of this achievement is the MIMOSA Pro, the only vascular assessment tool that combines tissue oxygenation, thermography, wound area reduction, and high-resolution digital imaging in a single, pocket-sized device. This innovation allows clinicians to make rapid, data-driven decisions at the point of care, ensuring better perfusion and oxygenation for wounds treated with skin substitutes. The recognition of the MIMOSA Pro in this landmark ruling underscores its role as a game-changer in wound care technology. Congratulations to LSI Alumni Dr. Karen Cross and the MIMOSA Diagnostics team! To dive deeper into MIMOSA’s mission and innovation, watch Dr. Karen Cross’s past LSI presentations on our website and YouTube channel. Connect with Dr. Karen Cross directly at LSI USA '25, held March 17-21 in Dana Point, California.